Table 1 Clinical characteristics of prostate cancer patients treated with ADT (n = 290)
Parameters | No. of patients (%) |
|---|---|
Age (median, interquartile range), years | 75 (67–79) |
PSA (median, interquartile range), μg/L | 100.00 (31.13–198.50) |
Gleason Score | |
  < 7 | 36 (12.41) |
 7 | 108 (37.24) |
  > 7 | 146 (50.35) |
Metastasis | |
 No | 159 (54.83) |
 Yes | 131 (45.17) |
Risk Stratification | |
 Low | 1 (0.34) |
 Intermediate | 27 (9.31) |
 High | 262 (90.35) |
Platelet (median, interquartile range), 109/L | 181.50 (145.00–215.25) |
Lymphocyte (median, interquartile range), 109/L | 1.54 (1.21–1.89) |
PLR | 117.46 (87.26–154.57) |
Progression-free survival | 126 (43.45) |
Cancer-specific survival | 60 (20.69) |
Overall survival | 70 (24.14) |
Follow-up time (months) | 37.00 (24.00–50.30) |